Workflow
梁军出任CEO,昉擎科技完成数亿元天使轮融资|投融资周报
2 1 Shi Ji Jing Ji Bao Dao·2025-08-05 05:59

Group 1 - The trend in the investment market shows a continuous interest in smart robotics, advanced manufacturing, and innovative pharmaceutical companies, with significant financing activities reported [1] - Shanghai Fangqing Technology recently completed several hundred million RMB in angel round financing, focusing on artificial intelligence computing [18] - Shanghai Chengfan Pharmaceutical announced over $60 million in Pre-A+ round financing, led by Shunwei Capital, to advance its core pipeline into global clinical trials [10] Group 2 - From July 28 to August 3, 2025, there were 22 financing events in the domestic primary market, with a total scale of approximately 3.873 billion RMB [2] - The semiconductor/chip sector completed 4 financing rounds totaling nearly 500 million RMB, while the robotics sector also completed 4 rounds totaling nearly 400 million RMB [3] - The medical device sector saw 2 financing rounds with disclosed amounts exceeding 600 million RMB [3] Group 3 - The majority of financing activities were concentrated in Jiangsu Province, Beijing, and Shanghai, with 6, 5, and 4 cases respectively [4] - Active investment institutions included Huatai Zijin, Yahui Investment, and Lingang Science and Technology Investment, each completing 2 financing rounds primarily in the healthcare and technology sectors [5] Group 4 - Suzhou Yinhang Biotechnology completed over 100 million RMB in financing to accelerate new product commercialization and global market expansion [9] - Nanjing Puli Medical Technology completed nearly 300 million RMB in C round financing, focusing on high-performance medical polymer materials [14] - Beijing Ruisi Zhili Technology announced several million RMB in financing to enhance its AI infrastructure research and market expansion [15]